Favorable toxicity profile of raltitrexed in elderly patients treated for colorectal cancer: A case series

Gerontology

Volumn 49, Issue 5, 2003, Pages 324-327

  Franchi, Fabrizio ^a,b   Pastore, C ^a   Caporale, A ^a   Fabiani, O ^a   Rossi, L ^a   Seminara, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

Chemotherapy, elderly; Colorectal cancer; Raltitrexed

Indexed keywords

RALTITREXED;

ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOSAFETY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; ELDERLY CARE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; INTOXICATION; LEUKOPENIA; LIVER DISEASE; LOW DRUG DOSE; MALE; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; QUINAZOLINES; THIOPHENES; TREATMENT OUTCOME;

EID: 0041885257     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071714     Document Type: Article

References (28)

1. Cunnigham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, Azab M, Seymour L, Lowery K: Tomudex (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995;31A:1945-1954.
2. Zalcberg JR, Cunnigham D, Van Cutsem E, François E, Schornagel J, Adenis A, Green M, Iveson A, Azab M, Seymour I: ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996;14:716-721.
3. Kerr DJ: Clinical efficacy of 'Tomudex' (ralti-trexed) in advanced colorectal cancer. Anticancer Drugs 1997;8(suppl):11-15.
4. Ross P, Heron J, Cunnigham D: Cost of treating colorectal cancer: A prospective comparison of treatment regimens. Eur J Cancer 1996:32A(suppl):13-17.
5. Elliott R: An analysis of drug costs for the management of chemotherapy related side effects in advanced colorectal cancer. J Oncol Pharm Pract 1996;2:186-190.
6. Kerr D, O'Connor KM: An economic comparison of the net clinical benefit and treatment costs of raltitrexed and 5-fluorouracil + leucovorin (Mayo regimen) in advanced colorectal cancer. J Med Econ 1999;2:123-132.
7. Zalcberg J: Overview of the tolerability of 'Tomudex' (raltitrexed): Collective clinical experience in advanced colorectal cancer. Anticancer Drugs 1997;8(suppl):17-22.
8. Cunnigham D: Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer 1998;77(suppl):15-21.
9. Blackledge G: New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex'). Br J Cancer 1998;77(suppl):29-37.
10. Topham C, Moore J: Patient preferences for chemotherapy schedules used in the treatment of advanced colorectal cancer: A pilot study. Eur J Cancer Care 1997;6:291-294.
11. Fentiman IS, Tirelli U, Monfardini S, Schneider M, Festen J, Cognetti F, Aapro MS: Cancer in the elderly: Why so badly treated? Lancet 1990;335:1020-1022.
12. Editorial: Drug-company decision to end cancer trial. Lancet 1999;354:1045.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
14. Begg CB, Carbone PP: Clinical trials and drug toxicity in the elderly: The experience of the Eastern Cooperative Oncology Group. Cancer 1983;52:1986-1992.
15. Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC, Sanguineti O, Repetto L, Rosso R: Advanced colorectal cancer in the elderly: Results of consecutive trials with 5-fluorouracil based chemotherapy. Cancer Chemother Pharmacol 1998;42:336-340.
16. Clarke SJ, Hanwell J, De Boer M, et al: Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 1996;14:1495-1503.
17. Fata F, Mirza A, Craig G, Nair S, Law A, Gallagher J, Ellison N, Bernath A: Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: A 10-year experience of the Geisinger Medical Center. Cancer 2002;94:1931-1938.
18. Popescu RA, Norman A, Ross PJ, Parikh B, Cunnigham D: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999;17:2412-2418.
19. De Gramont A, Figer A, Seymour M: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
20. Giacchetti S, Perpoint B, Zidani R: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147.
21. Douillard JY, Cumingham D, Roth AD: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomised trial. Lancet 2000;355:1041-1047.
22. Saltz LB, Cox JV, Blanke C: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
23. Scheithauer W, Rosen H, Kornek GV, et al: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752-755.
24. Smyth JF, Hardcastle JD, Denton G, et al: Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Ann Oncol 1995;6:948-949.
25. Franchi F, Pastore C, Izzo P, Caliò E: Ca 19-9 in the monitoring of colorectal cancer after surgery. Med Oncol 2001;18:237-238.
26. Maughan T, James R, Kerr D, Ledermann J, McArdle C, Seymour M, Johnston C, Stephens R: Excess treatment-related deaths and impaired quality of life show raltitrexed is inferior to infusional 5-FU regimens in the palliative chemotherapy of advanced colorectal cancer (CRC): Final results of MRC CR06. Ann Oncol 2000;11(suppl):43.
27. Raderer M, Fiebiger W, Wrba F, Scheithauer W: Fatal liver failure after administration of raltitrexed for cancer chemotherapy. Cancer 2000;89:890-892.
28. Judson I, Maughan T, Beale P, Primrose J, Hoskin P, Hanwell J, Berry C, Walker M, Sutcliffe F: Effects of impaired renal function on the pharmacokinetics of raltitrexed. (Tomudex ZD1694). Br J Cancer 1998;78:1188-1193.